Helper plasmids for production of HIV-1-derived vectors

被引:21
作者
Fuller, M [1 ]
Anson, DS [1 ]
机构
[1] Womens & Childrens Hosp, Dept Chem Pathol, Adelaide, SA 5006, Australia
关键词
D O I
10.1089/10430340152677421
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Vectors derived from human immunodeficiency virus type 1 (HIV-1) appear an attractive option for many gene therapy applications. This is due to their ability to transduce noncycling cell populations and to integrate their genome into the host cell chromosome, resulting in the stable genetic modification of the transduced cell. These properties have permitted the direct in vivo transduction of several tissues, including the central nervous system, retina, and liver. However, the pathogenic nature of HIV-1 has raised considerable concerns about the safety of such vector systems. To help address these concerns, we have expressed each of the primary transcriptional units encoding trans functions relevant for vector production in individual plasmid constructs. The gag-pol gene sequence was codon-optimized for expression in mammalian cells resulting in high level Rev/Rev-response element (RRE) -independent expression. Codon optimization of gag-pol also reduces sequence homology with vectors containing gag gene sequences, which results in reduced transfer of biologically active gag-pol sequences to transduced cells. Furthermore, the vif reading frame overlapping the 3' end of the pol coding sequence is destroyed by codon optimization. We have also shown that the Gag and Gag-Pol polyproteins can be efficiently expressed from separate transcriptional units. This has enabled the removal of a cis-acting viral element, the gag-pol translational frameshift sequence, from the vector/packaging system and prevents detectable transfer of biologically active sequences equivalent to the gag-pol gene to transduced cells.
引用
收藏
页码:2081 / 2093
页数:13
相关论文
共 41 条
[1]  
Ausubel FA, 1995, CURRENT PROTOCOLS MO
[2]  
Blomer U, 1997, J VIROL, V71, P6641
[3]   Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system [J].
Chang, LJ ;
Urlacher, V ;
Iwakuma, T ;
Cui, Y ;
Zucali, J .
GENE THERAPY, 1999, 6 (05) :715-728
[4]   Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins [J].
Chinnasamy, D ;
Chinnasamy, N ;
Enriquez, MJ ;
Otsu, M ;
Morgan, RA ;
Candotti, F .
BLOOD, 2000, 96 (04) :1309-1316
[5]   Regulated expression vectors demonstrate cell-type-specific sensitivity to human immunodeficiency virus type 1 Nef-induced cytostasis [J].
Cooke, SJ ;
Coates, K ;
Barton, CH ;
Biggs, TE ;
Barrett, SJ ;
Cochrane, A ;
Oliver, K ;
McKeating, JA ;
Harris, MPG ;
Mann, DA .
JOURNAL OF GENERAL VIROLOGY, 1997, 78 :381-392
[6]   HIGH-TITER PACKAGING CELLS PRODUCING RECOMBINANT RETROVIRUSES RESISTANT TO HUMAN SERUM [J].
COSSET, FL ;
TAKEUCHI, Y ;
BATTINI, JL ;
WEISS, RA ;
COLLINS, MKL .
JOURNAL OF VIROLOGY, 1995, 69 (12) :7430-7436
[7]   Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function [J].
Cui, Y ;
Iwakuma, T ;
Chang, LJ .
JOURNAL OF VIROLOGY, 1999, 73 (07) :6171-6176
[8]   A third-generation lentivirus vector with a conditional packaging system [J].
Dull, T ;
Zufferey, R ;
Kelly, M ;
Mandel, RJ ;
Nguyen, M ;
Trono, D ;
Naldini, L .
JOURNAL OF VIROLOGY, 1998, 72 (11) :8463-8471
[9]   Tat is required for efficient HIV-1 reverse transcription [J].
Harrich, D ;
Ulich, C ;
GarciaMartinez, LF ;
Gaynor, RB .
EMBO JOURNAL, 1997, 16 (06) :1224-1235
[10]   Self-inactivating lentiviral vectors with U3 and U5 modifications [J].
Iwakuma, T ;
Cui, Y ;
Chang, LJ .
VIROLOGY, 1999, 261 (01) :120-132